Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to ad5 and protect nonhuman primates against ebolavirus challenge

Journal of Virology

Volumn 85, Issue 9, 2011, Pages 4222-4233

  Geisbert, Thomas W ^a   Bailey, Michael ^b   Hensley, Lisa ^a   Asiedu, Clement ^b   Geisbert, Joan ^a   Stanley, Daphne ^b   Honko, Anna ^a   Johnson, Joshua ^a   Mulangu, Sabue ^b   Pau, Maria Grazia ^c   Custers, Jerome ^c   Vellinga, Jort ^c   Hendriks, Jenny ^c   Jahrling, Peter ^b   Roederer, Mario ^b   Goudsmit, Jaap ^c   Koup, Richard ^b   Sullivan, Nancy J ^b  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c CRUCELL HOLLAND BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; EBOLA VACCINE; GLYCOPROTEIN;

ADENOVIRUS SEROTYPE 26; ADENOVIRUS SEROTYPE 35; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; EBOLA VIRUS; GENE CONSTRUCT; GENE SEGREGATION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; MACACA; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; PROTECTION; SEROPREVALENCE; SINGLE DRUG DOSE; T LYMPHOCYTE; TREATMENT DURATION; VACCINATION; VIRUS PARTICLE; VIRUS RECOMBINANT;

ADENOVIRUSES, HUMAN; ANIMALS; ANTIBODIES, VIRAL; DRUG CARRIERS; EBOLA VACCINES; GENETIC VECTORS; HEMORRHAGIC FEVER, EBOLA; LYMPHOCYTES; MACACA FASCICULARIS; VACCINATION; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS;

ADENOVIRIDAE; EBOLA VIRUS; PRIMATES;

EID: 79955387781     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02407-10     Document Type: Article

References (51)

1. Abbink, P., et al. 2007. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 81:4654-4663.
2. Asmuth, D. M., et al. 2010. Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens. J. Infect. Dis. 201:132-141.
3. Barouch, D. 2009. First-in-human phase 1 safety and immunogenicity of an adenovirus serotype 26 HIV-1 vaccine vector. AIDS Vaccine 2009, Paris, France, 19-22 October 2009.
4. Barouch, D. H., et al. 2004. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol. 172:6290-6297.
5. Buchbinder, S. P., et al. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881-1893.
6. Catanzaro, A. T., et al. 2006. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J. Infect. Dis. 194:1638-1649.
7. Cheng, C, et al. 2007. Mechanism of Ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells. PLoS Pathog. 3:e25.
8. + T cell-stimulating skin-emigrated dendritic cells. J. Immunol. 177:2208-2215.
9. Fallaux, F. J., et al. 1996. Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum. Gene Ther. 7:215-222.
10. Geisbert, T. W., et al. 2010. Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates. J. Virol. 84:10386-10394.
11. Geisbert, T. W., D. G. Bausch, and H. Feldmann. 2010. Prospects for immunisation against Marburg and Ebola viruses. Rev. Med. Virol. 20:344-357.
12. Harro, C, et al. 2009. Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults. Clin. Vaccine Immunol. 16:1285-1292.
13. Havenga, M., et al. 2006. Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells. J. Gen. Virol. 87:2135-2143.
14. Hill, A. V., et al. 2010. Prime-boost vectored malaria vaccines: progress and prospects. Hum. Vaccin. 6:78-83.
15. Jin, T. H., E. Tsao, J. Goudsmit, V. Dheenadhayalan, and J. Sadoff. 2010. Stabilizing formulations for inhalable powders of an adenovirus 35-vectored tuberculosis (TB) vaccine (AERAS-402). Vaccine 28:4369-4375.
16. Kibuuka, H., et al. 2010. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-uninfected East Africans (RV 172). J. Infect. Dis. 201:600-607.
17. Kostense, S., et al. 2004. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 18:1213-1216.
18. Koup, R. A., et al. 2010. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One 5:e9015.
19. Larkin, M. A., et al. 2007. Clustal W and Clustal X version 2.0. Bioinformatics 23:2947-2948.
20. Lasaro, M. O., and H. C. Ertl. 2009. New insights on adenovirus as vaccine vectors. Mol. Ther. 17:1333-1339.
21. Ledgerwood, J. E., et al. 2010. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 29:304-313.
22. Lemckert, A. A., et al. 2005. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J. Virol. 79:9694-9701.
23. + dendritic cells but show redundancy in their requirement of TLR and nucleotide-binding oligomerization domain-like receptor signaling. J. Immunol. 185:1513-1521.
24. Liu, J., et al. 2008. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J. Virol. 82:4844-4852.
25. Liu, J., et al. 2009. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457:87-91.
26. Lore, K., et al. 2007. Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses. J. Immunol. 179:1721-1729.
27. Maizel, J. V., Jr., D. O. White, and M. D. Scharff. 1968. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 36:115-125.
28. Mast, T. C, et al. 2010. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 28:950-957.
29. McCoy, K., et al. 2007. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J. Virol. 81:6594-6604.
30. Nanda, A., et al. 2005. Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys. J. Virol. 79:14161-14168.
31. National Research Council. 1996. Guide for the care and use of laboratory animals, DHEW publication no. NIH 86-23. National Academy Press, Washington, DC.
32. Ophorst, O. J., et al. 2006. Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice. Infect. Immun. 74:313-320.
33. Peiperl, L., et al. 2010. Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054). PLoS One 5:e13579.
34. Perfetto, S. P., et al. 2006. Amine reactive dyes: an effective tool to discriminate live and dead cells in polychromatic flow cytometry. J. Immunol. Methods 313:199-208.
35. Radosevic, K., et al. 2007. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infect. Immun. 75:4105-4115.
36. Rao, B. L., et al. 2004. A large outbreak of acute encephalitis with high fatality rate in children in Andhra Pradesh, India, in 2003, associated with Chandipura virus. Lancet 364:869-874.
37. Rodriguez, A., et al. 2009. Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys. Vaccine 27:6226-6233.
38. Rodriguez, L. L., T. A. Bunch, M. Fraire, and Z. N. Llewellyn. 2000. Re-emergence of vesicular stomatitis in the western United States is associated with distinct viral genetic lineages. Virology 271:171-181.
39. Santra, S., et al. 2005. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J. Virol. 79:6516-6522.
40. Santra, S., et al. 2009. Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. Vaccine 27:5837-5845.
41. Shiver, J. W., et al. 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415:331-335.
42. Shott, J. P., et al. 2008. Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice. Vaccine 26:2818-2823.
43. Sprangers, M. C., et al. 2003. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J. Clin. Microbiol. 41:5046-5052.
44. Sullivan, N. J., et al. 2006. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med. 3:e177.
45. Sullivan, N. J., et al. 2003. Accelerated vaccination for Ebola virus haemor-rhagic fever in non-human primates. Nature 424:681-684.
46. Sullivan, N. J., J. E. Martin, B. S. Graham, and G. J. Nabel. 2009. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat. Rev. Microbiol. 7:393-400.
47. Sullivan, N. J., A. Sanchez, P. E. Rollin, Z. Y. Yang, and G. J. Nabel. 2000. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408:605-609.
48. Thorner, A. R., et al. 2006. Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity. J. Virol. 80:12009-12016.
49. U.S. Department of Agriculture. 1966. Laboratory Animal Welfare Act, publication L-89-544. U.S. Department of Agriculture, Washington, DC.
50. Vogels, R., et al. 2007. High-level expression from two independent expression cassettes in replication-incompetent adenovirus type 35 vector. J. Gen. Virol. 88:2915-2924.
51. Vogels, R., et al. 2003. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J. Virol. 77:8263-8271.